Fig. 2

Pyrotinib monotherapy exhibits an insufficient anti-tumor effect in PDAC cell lines in vitro and PDX in vivo. A, B HER2 expression were exhibited using qPCR and western blot in one immortalized pancreatic ductal cell (HPNE) and seven PDAC cell lines. C, D PDAC cell lines were treated with increasing concentrations of pyrotinib. Colony formation assay were conducted (C) and IC50 were calculated (D). E–I one patient-derived xenograft (PDX02) was planted in BALB/c nude mice and the fifth passage mice were delivered with vehicle (n = 7), trastuzumab (10 mg/kg, intraperitoneal injection; once every two days, n = 5), pyrtonib (40 mg/kg or 80 mg/kg respectively, oral gavage; every day, n = 5 each) for 21 days. Growth curve and endpoint tumor volume were delivered in (E) and (F–H). Body weight curve were delivered in (I). Data are represented as mean ± SEM. Statistical significance were assessed using a Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns not significant